ASGE Postgraduate Course at ACG: Evidence-based Updates for the Practicing Gastroenterologist (On-Demand) | October 2021 OLPGATACG21-Endoscopic Surveillance and Management of Colitis-Associated Neoplasia

Endoscopic Surveillance and Management of Colitis-Associated Neoplasia

Video Transcription

Video Summary

In this video, Dr. Amandeep Shergil discusses endoscopic surveillance and management of colitis-associated neoplasia. He highlights the importance of documenting endoscopic remission and defines remission criteria for ulcerative colitis (UC) and Crohn's disease. He explains the Montreal classification and its relevance in determining eligibility for surveillance programs. Dr. Shergil emphasizes the use of standardized descriptors for mucosal inflammation and the various terms used to describe dysplastic lesions. He discusses the use of chromoendoscopy with targeted biopsy sampling as the preferred technique for detecting dysplasia and compares it to white-light colonoscopy with random biopsy sampling. He also discusses the role of random biopsies and their importance in maximizing dysplasia detection in high-risk groups. Dr. Shergil touches on the management of endoscopically detectable lesions and recommends endoscopic resection for resectable lesions while considering referral to an advanced endoscopist for complex cases. He concludes by discussing surveillance intervals and recommendations for follow-up colonoscopies.

Asset Subtitle

Amandeep K. Shergill, MD

Keywords

endoscopic surveillance

colitis-associated neoplasia

Montreal classification

chromoendoscopy

dysplastic lesions

follow-up colonoscopies